drugset / Trial / NCT00506922

Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT

NCT00506922

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Primary Objective: 1\. To determine efficacy of escalating doses of pentostatin in combination with tacrolimus and methotrexate for the prevention of acute graft-versus-host disease (GVHD) in the context of unrelated donor and one antigen mismatched related donor transplantation. Secondary Objectives: 1. To determine safety of escalating doses of pentostatin in combination with tacrolimus and methotrexate. 2. To reduce the incidence of acute GVHD following transplants with unrelated donor to 40%. 3. To document blood levels of tacrolimus when combined with pentostatin.

Timeline

Start
2000-09
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentostatin Small molecule 0.5 mg/m2 Intravenous
Subject Pentostatin Small molecule 1 mg/m2 Intravenous
Subject Pentostatin Small molecule 1.5 mg/m2 Intravenous
Subject Pentostatin Small molecule 2 mg/m2 Intravenous
Subject Tacrolimus Small molecule Intravenous
Background Methotrexate Small molecule 5 mg/m2 Intravenous

Indications